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Abstract
During drug development, matching adult systemic exposures of drugs is a common approach for 
dose selection in pediatric patients when efficacy is partially or fully extrapolated. This is a 
systematic review of approaches used for matching adult systemic exposures as the basis for dose 
selection in pediatric trials submitted to the U.S. Food and Drug Administration (FDA) between 
1998 and 2012. The trial design of pediatric pharmacokinetic (PK) studies and the pediatric and 
adult systemic exposure data were obtained from FDA publicly available databases containing 
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reviews of pediatric trials. Exposure matching approaches that were used as the basis for pediatric 
dose selection were reviewed. The PK data from the adult and pediatric populations were used to 
quantify exposure agreement between the two patient populations. The main measures were the 
pediatric PK studies trial design elements and drug systemic exposures (adult and pediatric). There 
were 31 products (86 trials) with full or partial extrapolation of efficacy with an available PK 
assessment. Pediatric exposures had a range of mean Cmax and AUC ratios (pediatric/adult) of 
0.63-4.19 and 0.36-3.60 respectively. Seven of the 86 trials (8.1%) had a pre-defined acceptance 
boundary used to match adult exposures. The key PK parameter was consistently predefined for 
antiviral and anti-infective products. Approaches to match exposure in children and adults varied 
across products. A consistent approach for systemic exposure matching and evaluating pediatric 
PK studies is needed to guide future pediatric trials.
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Introduction
Extrapolation of efficacy findings from adults to the pediatric population is an approach that 
was first proposed by the U.S. Food and Drug Administration (FDA) in the 1994 Pediatric 
Labeling Rule to maximize the use of adult and other data when designing pediatric drug 
development programs. The Rule was supplanted by the Best Pharmaceuticals Children's 
Act (BPCA) in 2002 and Pediatric Research Equity Act (PREA) in 2003. These 
requirements and incentives were made permanent as of 2012 with the passing of the FDA 
Safety and Innovation Act (FDASIA). The extrapolation concept was reflected in 
Regulations under 21 CFR 314.55 and has been further described in a pediatric study 
planning algorithm published by the FDA.1
Extrapolation of efficacy from adults to pediatric patients relies on the assumptions that the 
course of the disease and the response to the investigational drug are sufficiently similar 
between the adult and intended pediatric population. Based on the sufficiency of the data in 
support of these assumptions, extrapolation of efficacy from adequate, well-controlled 
studies with adults to the pediatric population can be categorized as either full extrapolation 
or partial extrapolation. In either circumstance, a pharmacokinetic (PK) study in the relevant 
age group may be conducted to determine dosing in the pediatric population. In 2011, the 
experience of the FDA in interpreting the use of extrapolation of efficacy in pediatric drug 
development programs was reviewed.2 Extrapolation of efficacy from adult data occurred for 
82.5% of the drug products (137 of 166). Extrapolation was defined as full for 14.5% of the 
products (24 of 166) and partial for 68% (113 of 166). When extrapolation was used, a 
larger percentage (61%) of the drug products (84 of 137) obtained a new pediatric indication 
or extension into a new age group, but this number decreased to 34% (10 of 29) when there 
was no extrapolation.
A key component for both partial and full extrapolation is selecting dosing regimens that 
achieve pediatric exposures “similar” to adults.1 A dosing regimen must be identified that 
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results in an exposure range or distribution comparable to what has been observed in the 
reference population, most often adults. However, currently guidance is lacking about the 
best methods for matching adult systemic exposures in pediatric studies. The objective of 
this study was to examine prior approaches to exposure matching and exposure agreement 
for adult and pediatric patients as the basis for pediatric dose selection for trials submitted to 
the FDA under BPCA from 1998 to 2012 and PREA from 2007 to 2012.
Methods
Clinical Trials Selection
Pediatric trials that used full extrapolation of efficacy or partial extrapolation of efficacy 
with confirmation of response were included in our reviews. Pediatric trials submitted to the 
Agency in response to written requests (WR) issued by the FDA under the Pediatric 
Exclusivity Provision between February 1998 and August 31, 2012 and in response to PREA 
between September 27, 2007 and August 31, 2012 were included. Locally acting products 
(e.g., nasal sprays, ophthalmic drops, etc.) were excluded from our review because PK for 
locally acting drugs is more often related to safety and less correlated with efficacy. Clinical 
pharmacology reviews were retrieved for each product from the FDA public database either 
containing medical, statistical, and clinical pharmacology reviews of pediatric trials 
submitted to FDA (http://www.fda.gov/scienceresearch/specialtopics/
pediatrictherapeuticsresearch/default.htm) or containing reviews for FDA approved drug 
products (http://www.accessdata.fda.gov/Scripts/cder/drugsatfda/index.cfm). Products for 
which mean values of PK parameters and a measure of variability in the relevant pediatric 
age group and the reference adult population were reported in the clinical pharmacology 
review were included. Products lacking these data were excluded from this review.
For the purpose of this study, the pediatric population was defined as the collective pediatric 
age group from birth to 16 years of age (21 CFR201.57 (f) (9)). Subgroups of pediatric 
patients based on age may be identified in pediatric study planning based upon expected 
differences in PK or drug response.
Data Extraction
Available data on the design and conduct of the PK study including criteria for exposure 
matching, key exposure metric(s), justification for the target systemic exposure, and/or post-
hoc acceptance criteria for a no clinically meaningful effect boundary were obtained from 
the FDA clinical pharmacology review for each product. Reported systemic exposure data 
(e.g., Cmax, AUC) of the parent drug when applicable in the relevant pediatric and adult 
populations were extracted. Other data pertinent to the therapeutic class of the product, 
indication, age group and doses studied, and discussion of the PK results were captured. 
Development of dosing recommendations, including the FDA reviewer's assessment of 
whether dosage adjustment is warranted in pediatric patients was included when available. 
When available, additional exposure-response information used to support an argument that 
observed differences in systemic exposure would be too small to affect the pediatric 
response and, therefore, no dose or dose regimen adjustments were appropriate in the 
studied pediatric population was captured.
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Mean and variance exposure measures from each study were extracted for both the pediatric 
and referenced adult population to derive the relative mean exposure ratios and associated 
90% confidence intervals (CIs). The 90% CIs for exposure ratios were constructed using the 
Fieller's method (PROC TTEST in SAS 9.3, SAS Institute, Cary, NC). Studies with 
variability reported as standard deviation (SD) or percent coefficient of variation (%CV) 
were included in the analysis. For a larger proportion of studies included in this analysis, the 
arithmetic means rather than the geometric means were reported. Since patient level data 
were not available and the summary statistics provided were mixed (most were arithmetic 
means), it was not possible to perform a detailed analysis and this has restricted our choice 
of methods. Consequently the statistical analysis results, specifically the 90% confidence 
intervals presented in this article, are exploratory in nature and should be interpreted as such. 
The Spearman's rank correlation coefficient was used to quantify the linear association 
between observed Cmax ratios and AUC ratios. The Bland-Altman plot was also used to 
graphically view the agreement between the two measures.
In order to evaluate concurrence between the FDA clinical pharmacology reviews and the 
study reports, electronically available study reports for products reviewed by the Agency 
between 2008 and 2012 were reviewed. Available data on the design and conduct of the PK 
study were retrieved and compared to data available in the clinical pharmacology reviews.
Results
Data from 31 products (86 trials) with full or partial extrapolation of efficacy with an 
available PK assessment were included in the analysis (see Figure 1). Of 31 products, 12 
(38.7%) relied completely on extrapolation of efficacy for labeling in one or more pediatric 
age groups while 19 (61.3%) relied on partial extrapolation of efficacy with confirmation of 
response and assessment of safety. In both forms of extrapolation, the pediatric dose was 
selected to match the adult systemic exposures. In the partial extrapolation studies, efficacy 
in pediatric patients was used as supporting evidence to support the efficacy observed in 
adults. In all cases, safety was assessed in the target pediatric population.
The majority of the products were antivirals (54.8%), antihistamines (12.5%), histamine H2-
receptor blockers (6.25%), and anti-infectives (6.25%). The rest of the products were 
analgesics, sedatives, proton pump inhibitors, and drugs in other drug classes. Of the 31 
products, 25 (78.1%) were studied in more than one pediatric age group. Thus, six products 
had clinical pharmacology reviews that included studies in only one age group for 
emtricitabine, famotidine, fentanyl transdermal system, midazolam, peg-interferon alfa-2b 
(alone), and ranitidine. A list of the products and the age groups studied is provided in 
Supplemental Table S1.
Of the 86 trials, 69 (80.3%) used intensive sampling strategy and performed a non-
compartmental analysis (NCA), 8 (9.3%) used a sparse sampling design and conducted 
population PK analysis (Pop PK) and 9 (10.4%) used both NCA and Pop PK analyses. 
Assessment of similarity between pediatric and adult systemic exposures in the clinical 
pharmacology review was based on a cross-study comparison. Adult data was obtained from 
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separate studies using either healthy volunteers or subjects with the condition/disease. Seven 
of the 86 trials (8.1%) had a pre-defined acceptance boundary used to match adult 
exposures. The boundary either included specific target values or an acceptable percentage 
of the adult exposure (i.e., 80% – 125% of the comparator value). For the remaining trials, 
the clinical pharmacology review did not explicitly outline the acceptable boundaries for 
exposure similarity. The key exposure metric was consistently predefined for antiviral and 
anti-infective products.
Of the 86 trials, 20 (23.3%) did not result in an indication in all or part of the population 
included in the trial. Of these, 13 had insufficient evaluation of efficacy, or qualitative 
efficacy was not demonstrated in the pediatric study. For the remaining 7 trials, an indication 
was not granted because dosing could not be established in part or all of the population 
included in the study or an insufficient number of subjects were included in the study. Of the 
66 (76.7%) that resulted in an indication in the studied pediatric population, the dose studied 
was the dose approved for 48 (72%) of the trials. The majority of the dose modifications 
were a result of the FDA clinical pharmacology reviewer's assessment that the pediatric 
exposures did not match the adult reference exposures. In a few cases, the modifications 
were to provide a fixed dose recommendation for the specific weight bands that would 
match the dose studied in the trial. Regardless of the rationale for dose modification, 
modeling and simulation was used post-hoc to derive a potentially unstudied pediatric 
dosing strategy that meets exposure-matching criteria using available adult and pediatric 
data. A list of approved doses for the indications studied is provided in Supplemental Table 
S1.
Pediatric exposures for approved doses were generally higher than adults for most studies in 
this dataset (Figure 2-4). The range of the mean Cmax ratios (Pediatric/Adult) were 
0.63-4.19 and the range of the mean AUC ratios (Pediatric/Adult) were 0.36-3.60. In several 
cases, the review included statements that the observed difference in systemic exposure was 
unlikely to result in clinically significant difference in outcome. Typically, language stating 
that the proposed dose was found to be appropriate was used in the absence of actual 
examined exposure criteria.
In the 86 trials, there were a total of 90 age groups for which complete information for both 
Cmax and AUC was available. The Bland and Altman plot revealed an agreement between 
Cmax ratios and AUC ratios for these 90 groups. Figure 5 displays a scatter diagram of the 
differences between the AUC and Cmax ratios against the averages of the two 
measurements. The two red horizontal lines are the limits of agreement, which are defined as 
the mean difference plus and minus 1.96 times the standard deviation of the differences. 
Because the majority of the observations are within these limits and clustered around zero, 
there appears to be good agreement between the two measures. The Spearman's rank 
correlation coefficient between Cmax ratios and AUC ratios was 0.85 (p<0.001) implying a 
strong linear association between the two ratios.
In order to evaluate concurrence between the FDA clinical pharmacology review and the 
study report, electronically available study reports were compared to clinical pharmacology 
reviews. Of the 10 products included in the analysis with a study report submission date 
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after 2008, 8 had protocols available electronically for review. Of these, 6 (75%) had 
complete concordance between the clinical pharmacology review and the protocol. For 2 out 
of 8 (25%) of the products, the pre-specified criteria was discussed in the study protocol but 
not in the FDA clinical pharmacology reviews.
The case of tipranavir illustrates the many considerations other than simple exposure 
matching that influence review and approval of pediatric doses. Furthermore, it provides an 
example where doses that were not directly studied were included in labeling. Pediatric 
approval of tipranavir was based on the results of an open-label clinical trial of two doses of 
tipranavir (290 mg/m2 and 375 mg/m2) with low dose ritonavir in HIV-infected children 2 to 
18 years of age. Although the low dose (290 mg/m2) reasonably matched adult exposure at 
the approved adult dose of 500 mg, the higher dose (375 mg/m2) was ultimately approved 
for pediatric use. This decision was supported by the exposure-response relationships for 
efficacy and safety and the desire to maximize benefit in a treatment-experienced population 
with resistance to more than one protease inhibitor. A body weight based dosing regimen 
was also included in labeling because it was thought that dosing based on weight would be 
more convenient than BSA in some healthcare settings. Simulations were used to predict the 
distribution of minimum concentrations under various body weight dosing regimens. These 
predictions were compared to a therapeutic window based on exposure-response 
relationships. This exercise resulted in the approval of a 14 mg/kg dose that was predicted to 
provide similar exposures to the 375 mg/m2 dose. The experience with tipranavir 
demonstrates the importance of collecting quality PK data to enable exposure-response 
modeling and dosing simulations and highlights the regulatory flexibility that enables the 
consideration of factors beyond exposure matching.
Another example which illustrates the challenges with matching adult systemic exposures in 
infants and neonates is the case of nelfinavir. Four studies were conducted to evaluate twice 
daily (BID) and three times daily (TID) dosing of nelfinavir in pediatric patients, including 
infants less than 2 years of age. Results from all pediatric studies were characterized by high 
inter-individual PK variability as was observed in the adult population. However, variability 
was highest in infants and neonates. In addition, none of the doses studied in this younger 
age group reliably achieved the target nelfinavir exposure associated with efficacy in adult 
studies (arithmetic mean AUC of 44 and 53 μg*hr/mL in two studies). An additional PK 
study in patients less than 2 years of age was not requested by the Agency because it would 
be unlikely that the additional data would allow selection of a dose for this age group. This 
assessment resulted in the lack of approval and dosing recommendation for nelfinavir use in 
pediatric patients less than 2 years of age.
Discussion
The use of extrapolation allows for a reduced number and complexity of studies to provide 
data sufficient for pediatric labeling.1, 2 As a result, extrapolation has been used increasingly 
in pediatric drug development over the last decade.3-8 Moreover, the use of extrapolation has 
resulted in a higher proportion of products obtaining new FDA labeling for pediatric use 
compared to products for which extrapolation was not used.2 This study reviewed the FDA's 
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experience with adult exposure matching as the basis for pediatric dose selection in pediatric 
clinical trials submitted to the Agency under BPCA and PREA.
In a prior review of the FDA's experience with pediatric extrapolation,2 the level of evidence 
in support of extrapolation and the type of studies used for pediatric labeling in 370 pediatric 
studies (166 products) conducted under the Pediatric Exclusivity Provision was assessed. 
Some form of extrapolation of efficacy from adult data was cited for the majority of the drug 
products (82.5%), with partial extrapolation used for 68% of the products and full 
extrapolation used for 14.5% of the products. For full extrapolation where there are 
sufficient data about the similarity of disease and response to the intervention, the evidence 
required to label the product for use in the pediatric population was PK and safety data or 
safety data in the relevant age group. For partial extrapolation, where there is some 
uncertainty about the similarity of disease and/or response to intervention, the evidence 
required for labeling was a “confirmation of efficacy” in addition to PK and safety data. For 
partial extrapolation, this confirmation of efficacy was either through a single, controlled or 
uncontrolled efficacy and safety trial, or a single exposure-response trial, in addition to PK 
and safety data.
PK differences between adults and some pediatric age groups are expected to occur since 
postnatal growth and development can affect drug disposition and action.9-12 Examples 
include developmental changes in metabolism including the maturation rate of Phase I and II 
enzyme activities, body composition such as water and lipid partitioning, receptor 
expression and function, growth rate, and organ functional capacity.13-16 PK studies are 
therefore essential to permit an assessment of the degree of impact of age-related 
differences.
The comparison of PK parameters between two populations or two products is discussed in 
several FDA Guidances for Industry: Drug Interactions (2012)17, Pharmacokinetics in 
Patients with Impaired Renal Function (2010)18, Bioavailability and Bioequivalence Studies 
for Orally Administered Drug Products (2003)9, Pharmacokinetics in Patients with Impaired 
Hepatic Function (2003)19 and Clinical Pharmacology Data to Support a Demonstration of 
Biosimilarity to a Reference Product20. An evaluation of confidence intervals for the mean 
difference in key exposure metrics such AUC and Cmax is a proposed approach in four out 
of the five guidance documents, with all four proposing a 90% CI of 80 to 125% for Cmax 
and AUC (Table 1) as an acceptable approach. This boundary of 80 to 125%9 may not be 
meaningful for many drugs and an acceptable boundary that better reflects the context of the 
therapeutic range of the drug and the risk-benefit of the product for a given pediatric 
indication would be more desirable. A delineation of a no effect boundary based on dose or 
concentration-response studies is proposed as an alternative method in the drug interaction 
and hepatic impairment guidances. Finally, the renal impairment guidance recommends 
mathematical modeling of the relationship between measures of renal function and the PK 
parameters of interest to provide a rational quantitative basis for dosage adjustment.
Exposure matching was an important part of pediatric extrapolation both for full and partial 
extrapolation. For these studies, information regarding study design and methods for 
assessing similarity of systemic exposures was highly variable. Given this heterogeneity, 
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mean exposure measures from each study were extracted for both the pediatric and 
referenced adult population to derive the relative exposure ratios and associated 90% CIs. 
Variability was not consistently reported or derivable from the available data.
The magnitude of systemic exposure similarity/dissimilarity varied within the same drug 
class and between different age groups for the same product. No specific trend was noted by 
therapeutic area or indication for systemic exposures on the extreme ends of the pediatric/
adult exposure ratio spectrum. Adult data was obtained from separate studies, either in 
healthy volunteers or in patients with the condition/disease. Insufficient information was 
available to evaluate whether the adult and pediatric study conditions (e.g. sampling scheme, 
inclusion/exclusion criteria, assays, etc.) were similar. Weight-based dosing was used in 
44.8% of the reviewed trials while BSA-based and fixed dosing strategies were used in 
24.1% and 31.1% of the trials, respectively.
As stated earlier, the 90% CIs for the exposure ratios were constructed using the Fieller's 
method. This method relies on the assumption of normality. However, because of the small 
sample sizes, the normality assumptions may not be valid. Additionally, for the majority of 
cases, the arithmetic mean ratios were used. Therefore, the 90% confidence intervals should 
be interpreted with caution.
The current study has some limitations. Our review was limited to information reported in 
FDA clinical pharmacology review documents, which are publicly available. Information 
that may influence the conclusion of this review may have been available at the study 
protocol or study report level. However, based on our review of a subset of the trials, there 
was complete concordance between the clinical pharmacology review and the protocol for 
the majority (75%) of the trials. Another possible limitation is that our review focused on 31 
products and as such the results of this study may not reflect approaches used in all 
therapeutic areas.
Antiviral agents and anti-infective agents comprised over 60% of the products in this 
evaluation. These classes of agents had consistently predefined the exposure matching 
criteria. Even so, a separate evaluation of exposure matching (manuscript in preparation) 
also found that precise matching of exposures in pediatric patients was generally not 
achieved in drug development studies.
Considering the frequency of use of exposure matching in pediatric studies, an assessment of 
(1) when the use of exposure matching is appropriate, and (2) establishment of a consistent 
approach to assess similarity between the reference population (usually adult) and the 
pediatric population is warranted.2, 16 Consideration should be given to the design and 
conduct of the pediatric study as well as the data analysis, presentation, and evaluation of 
results of exposure matching studies.
No official criteria have been established for selecting the appropriate metric and acceptance 
boundary for exposure matching and additional work will likely need to be done to clarify 
this approach. As stated above, a single acceptance boundary across drug products and drug 
classes will not provide a meaningful approach in this setting. Instead, when possible, the 
target exposure metric, range and acceptance criteria should be specified a priori and should 
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be defined in the context of the disease, treatment duration, route of administration and 
formulation in addition to other considerations. The assessment of exposure similarity can 
be an empirical comparison, similar to a bioequivalence type of approach discussed above 
where similarity is assessed based on comparison of observed adult and pediatric exposure 
data alone from a prospectively designed pharmacokinetic trial. An acceptance criterion is 
used to assess similarity based on the preset criteria. The limitations of this approach include 
the lack of ability to adjust for inter-study variability or to derive new dosing regimen if the 
initial criterion is not met. To overcome some of these challenges, a model-based approach 
can be used to integrate existing adult and pediatric pharmacokinetic data.
An alternative approach is a model based approach where using simulation, the model can 
explore a variety of pediatric dosing strategies to achieve a target exposure range, including 
those not directly studied in a pharmacokinetic trial. This approach provides flexibility and 
accounts for inter-study variability. Comparing means alone without consideration of 
population variability provides limited value in establishing exposure similarity. Instead, a 
simulation of the percent of subjects at different age/weight bins that lie within a pre-defined 
exposure range may provide a more meaningful assessment when appropriate. However, 
there are assumptions that are carried forward with model-based approaches and this 
approach requires confirmatory pediatric clinical studies unless there is sufficient clinical 
data to support the modeled dose (s).
Regardless of the approach, simulations can be used in the setting of exposure matching for 
extrapolation of efficacy to guide the design of pediatric trials including the sample size and 
sample scheme. Simulations should take into consideration that matching all exposure 
metrics may not often be feasible. Finally, regulatory flexibility has allowed the use of 
modeling and simulation post-hoc to derive a potentially unstudied pediatric dosing strategy 
that meets exposure-matching criteria using available PK and safety data.
Our retrospective analysis of historical trials in which pediatric drug exposures have been 
compared to adult reference populations suggests that past performance was variable. The 
practice of an NCA-based BE analysis using an adult reference population to anchor 
comparisons should probably evolve to accommodate more model-based approaches that 
reflect developmental influences on PK/PD. The target concentration (s) needed in pediatrics 
can be assessed a-priori and simulations can be conducted to assess the percentage of 
patients which would be within the target range. Data from a prospective pediatric clinical 
study can then be used to confirm simulation predictions. Adaptive study designs may 
provide utility in establishing dosing in pediatric patients especially in infants and neonates 
where PK predictions may be less reliable and large inter-patient variability is expected.
In summary, a review of 86 trials from 31 pediatric drug development programs completed 
and reviewed by the Agency between 1998 and 2012 demonstrated that various approaches 
to matching adult and pediatric exposures were used. For some drug classes (antivirals and 
anti-infectives), the key exposure metric for exposure matching was consistently predefined. 
Pediatric exposures ranges were 0.63-4.19 and 0.36-3.60 for Cmax ratios and AUC ratios, 
respectively.
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Distribution of products reviewed (1998-2012).
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Ratios (pediatric/adult) for Products Approved at the Studied Dose. The solid line 
corresponds to a ratio of one. The 90% confidence intervals are based on the Fieller's 
method.
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Forest Plot of Cmax and AUC Ratios (pediatric/adult) for Products without a Pediatric 
Indication. The solid line corresponds to a ratio of one. The 90% confidence intervals are 
based on the Fieller's method
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Forest Plot of Cmax and AUC Ratios (pediatric/adult) for Products Approved with a 
Different Dose. The solid line corresponds to a ratio of one. The 90% confidence intervals 
are based on the Fieller's method.
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Bland-Altman Plot of Cmax Pediatric/Adult Ratios and AUC Pediatric/Adult Ratios. Bland 
and Altman Plot of the data obtained from 90 age groups with Cmax pediatric/adult ratios 
and AUC pediatric/adult ratios; Correlation R = 0.85 (P<0.001). The blue line corresponds 
to the mean difference of the two ratios; the lower and the upper red lines correspond to the 
lower and the upper 95% confidence limits for the mean difference.
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Table 1
FDA Guidances Discussing Approaches for Matching Systemic Exposures
FDA Guidance Proposed Approach 1 Proposed Approach 2
Pharmacokinetics in Patients with 
Impaired Renal Function (Draft, 
2010)18
Mathematical modeling of the relationship 
between measures of renal function and PK 
parameters
Provide analysis of study data to show relevant PK 
measurements are similar
Bioavailability and Bioequivalence 
Studies Submitted in NDAs or 
INDs— General Considerations 
(Draft, 2014)9
Standard 90% CI of 80-125% for AUC and Cmax
Drug Interactions Guidance (Draft, 
2012)17
Specific no effect boundaries or clinical 
equivalence intervals; No effect boundaries 
represent the interval within which a change in 
systemic exposure is considered not clinically 
meaningful.
A no effect boundary of 90% CI of 80-125% for 
AUC and Cmax
Pharmacokinetics in Patients with 
Impaired Hepatic Function (Draft, 
2003)19
Delineation of a no effect boundary based on 
dose and/or concentration-response studies
Employment of a standard 90% CI of 80-125% for 
AUC and Cmax
Clinical Pharmacology Data to 
Support a Demonstration of 
Biosimilarity to a Reference 
Product20 (Draft, 2014)
Starting point for an acceptable limit for the 
confidence interval of the ratio may be 80–125%
Selection of the confidence interval and 
acceptance limits may vary among products. 
Alternatively, a similarity study with low, 
intermediate, and highest approved dose where a 
clear dose –response is observed. EC50, Emax, 
and slop of the concentration effect relationship 
should be evaluated for similarity.
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